Discovery of Pyrido[2,3-<i>d</i>]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment
作者:Yaoliang Sun、Manman Chen、Yuyan Han、Weiqiang Li、Xiaoyu Ma、Zihan Shi、Yang Zhou、Lan Xu、Lei Yu、Yuxiang Wang、Jinghua Yu、Xingxing Diao、Linghua Meng、Shilin Xu
DOI:10.1021/acs.jmedchem.3c02288
日期:2024.3.14
Despite progress in the discovery of ENPP1 inhibitors, the diversity in chemical structures and the efficacy of the agents are far from desirable, emphasizing the demand for novel inhibitors. Herein, we describe the design, synthesis, and biological evaluation of a series of ENPP1 inhibitors based on the pyrido[2,3-d]pyrimidin-7-one scaffold. Optimization efforts led to compound 31 with significant potency
外核苷酸焦磷酸酶/磷酸二酯酶 1 (ENPP1) 是一种胞外酶,负责水解环单磷酸鸟苷-单磷酸腺苷 (cGAMP),而环磷酸鸟苷是干扰素基因刺激剂 (STING) 途径的内源性激动剂。抑制 ENPP1 可以触发 STING 并促进抗肿瘤免疫,为癌症免疫治疗提供了一个有吸引力的治疗靶点。尽管 ENPP1 抑制剂的发现取得了进展,但化学结构的多样性和药物的功效远未达到预期,这凸显了对新型抑制剂的需求。在此,我们描述了一系列基于吡啶并[2,3- d ]pyrimidin-7-one支架的ENPP1抑制剂的设计、合成和生物学评价。通过优化工作,化合物31在体外抑制 ENPP1 和刺激 STING 通路方面均具有显着功效。值得注意的是, 31在同基因 4T1 小鼠三阴性乳腺癌模型中证明了体内功效。这些发现为癌症免疫疗法的进一步药物开发提供了一种有前途的先导化合物和新型支架。